Purpose: To evaluate the value of quantifying dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) heterogeneity to characterize adnexal masses. Materials and Methods: Our database was retrospectively queried to identify all surgically proven adnexal masses characterized with a 1.5T DCE-MRI between January 1st 2008 and February 28th 2010 (n 5 113 masses, including 52 benign, 11 borderline, and 50 invasive malignant tumors). The solid component of the adnexal mass was segmented. Quantitative analysis with a compartmental model was performed to calculate microvascular parameters, including tissue blood flow (F T ), blood volume fraction (V b ), lag time (D AT ), interstitial volume fraction (V e ), permeability-surface area product (PS), and relative area under curve ( r AUC), were calculated. Then heterogeneity parameters were evaluated using the analysis of the evolution of the standard deviation (SD) of signal intensities on DCE-MRI series. The area under the receiver operating characteristic (AUROC) curve was calculated to assess the overall discrimination of parameters. Results: Malignant tumors displayed higher F T , V b , and r AUC and lower D AT than benign tumors (P 5 0.01, P < 0.0001, and P < 0.0001, respectively). Invasive malignant tumors displayed lower V b and r AUC than borderline tumors (P < 0.01). After injection, whenever the heterogeneity parameter was considered, malignant tumors were more heterogeneous than benign tumors, invasive tumors were more heterogeneous than borderline ovarian tumors, and malignant tumors with carcinomatosis were more heterogeneous than tumors without carcinomatosis (P < 0.001). The most discriminant parameter was the SD during the 90 seconds after injection related to arterial input function (DSD EARLY/AIF ) with an AUROC between 0.715 and 0.808. Conclusion: This study proposes heterogeneity parameters as a new tool with a potential for clinical application, given that the technique uses routine imaging sequences. Level of Evidence: 3 Technical Efficacy: Stage 2
D
ynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) has proven to be a useful technique to characterize adnexal masses based on the lack of maturity of microvessels in malignant tumors. 1 A correlation has been demonstrated between DCE-MRI parameters and the pericyte coverage index and the presence of vascular endothelial growth factor receptor (VEGFR)-2 on both epithelial and endothelial cells. 2 Different methods of analysis have been published, including descriptive analysis (ie, time-intensity curve), semiquantitative analysis 2, 3 and quantitative analysis based on a compartmental model. [4] [5] [6] [7] The limitations of these techniques are the unavailability of reproducibility depending on acquisition parameters and the wide choice of pharmacokinetic models that may be used. Many years ago, Hricak et al described the enhancement heterogeneity of adnexal masses as a predictive parameter of ovarian cancer. 8 However, until now measurement of adnexal tumor heterogeneity is rarely done in clinical practice, although a visual impression of heterogeneity may often help the radiologist. Previous imaging studies have demonstrated that the analysis of tumor heterogeneity is useful in various organs, including breast, uterus, and lung. [9] [10] [11] [12] Moreover, a previous study demonstrated the usefulness of the added value of the evaluation of the heterogeneity on a T 2 -weighted(W)
MR sequence to DCE-MRI analysis to distinguish benign from malignant tumors in a small population of mixed ovarian tumors. 5 However, in that previous study the number of borderline ovarian tumors was too small to allow this subgroup of malignant tumors to be characterized.
The purpose of our study was to evaluate the value of the analysis of heterogeneity on DCE-MRI series to distinguish between benign, borderline, and malignant invasive ovarian tumors with and without carcinomatosis.
Materials and Methods

Patient Population
Our Institutional Ethics Committee approved this retrospective study and granted a waiver of informed consent. Between January 1st 2008 and February 28th 2010, our MRI database was retrospectively queried to identify women who underwent MRI with DCE imaging for ultrasound-complex adnexal masses with subsequent surgery and pathological correlation (n 5 275). Exclusion criteria were: DCE-MRI sagittal acquisition plane (n 5 101), masses without solid component Thomassin-Naggara et al.: Adnexal Tumor Vascular Heterogeneity (n 5 42), patients with histopathologically proven ovarian carcinoma (n 5 21), technical problems, including injection failure or artifact (n 5 6), and pregnancy (n 5 2). Thus, our final cohort included 103 patients (mean age: 52 years; age range: 17-88 years) (Fig. 1) .
At surgery, among these 103 patients ovarian cystectomy was performed in six women, salpingo-oophorectomy in 57 women (unilateral in 19 and bilateral in 38), salpingo-oophorectomy with hysterectomy in eight women (unilateral in two and bilateral in six), hysterectomy in one woman, salpingo-oophorectomy with hysterectomy and omentectomy in 14 women, pelvectomy in 10 women, and peritoneal biopsies in seven women.
Finally, histopathological findings showed 113 masses in the 103 patients, including 52 benign lesions (25 epithelial ovarian tumors, 15 ovarian sex-cord tumors, six teratomas, two tubal leiomyomas, three hydrosalpinx, and one peritoneal tuberculosis) and 61 malignant tumors (11 ovarian epithelial borderline tumors, 31 ovarian cystadenocarcinomas, four ovarian sex-cord stromal tumors, three immature germinal tumors, seven metastasis, and five tubal cancers) ( Table 1) .
MRI Technique
MRI sequences were acquired at 1.5T (Sonata, Siemens, Erlangen, Germany) using a phased array pelvic coil. Patients fasted for 3 hours and received an antispasmodic drug intravenously (Glucagen, 1 mg, Novo Nordisk, France) immediately before MRI to reduce bowel peristalsis.
The MR protocol systematically included sagittal T 2 W, axial T 2 W, axial T 1 W with and without fat suppression, and a T 1 W sequence after gadolinium injection. For the DCE-MRI sequence, images were obtained at 2.46-second intervals beginning 10 seconds before the bolus injection, for a total of 320 seconds and a total of 130 timeframes. The axial or axial oblique DCE T 1 -weighted gradient-echo sequence (2D FLASH) (TR 5 27, TE 5 2.24, flip angle 5 808, slice thickness 5 5 mm, interslice gap 5 1 mm, field of view [FOV] 5 400 3 200, matrix 5 256 3 128, NEX 5 1, number of slices 5 3) was acquired during a total acquisition time of 320 seconds through the tumor at the level where "solid tissue" was observed on nonenhanced MR images, as previously defined. 13 Gadolinium chelate (Dotarem, Guerbet, Aulnay, France) was given at a dose of 0.2 mL.kg 21 via a power injector (Medrad, Maastricht, The Netherlands) at a rate of 2 mL.s
21
, followed by 20 mL of normal saline to flush the tubing.
MRI Analysis
Dynamic data were analyzed using dedicated software developed in-house with MatLab 7.2 (R2006a; MathWorks, Natick, MA) named PhysioD3D 14 and running on a PC (Pentium 4 at 2.8
GHz and 2.5 GB of RAM memory). Two independent radiologists, with 1 and 10 years' experience in pelvic MRI, and no knowledge of the patient's clinical information performed the analysis independently. Two regions of interest (ROIs) were drawn for each examination: one containing the lumen of an external iliac artery (arterial input function [AIF] ) and another that included the whole tissue portion (WTP) of the ovarian tumor. We chose this method because individual arterial input functions could outperform population-averaged approaches for the pharmacokinetic modeling of DCE-MR images. [15] [16] [17] [18] Temporal signal curves of the AIF and the WTP were determined by calculating the mean MR signal in these regions over each of the 130 timeframes.
ROIs were drawn manually on one selected slice (from three), which corresponded to the maximum WTP surface, according to the visualized tissue on T 2 -weighted and postcontrast T 1 -weighted images. Then, to improve the delineation of the outer tumor margin and to avoid areas of necrosis, cysts, and nonvascularized tissue, we used a supervised segmentation tool based on mathematic k-means clustering 19 of the ROI into eight then five clusters, removing noisy clusters (motion at interfaces) and clusters without enhancement. The MR signal intensity of each pixel in the tumor for each one of the 130 timeframes of the sequence was reported into 130 spatial distributions (or histograms). For each distribution, statistical parameters including the mean value and the standard deviation (SD) were recorded ( Fig. 1) . SD provided an evaluation of the dispersion. We then generated curves from the 130 values for each of these statistical parameters. Then we determined the mean values over time of the statistical dispersion parameters, evaluating the SD (Fig. 2) . To include only the dispersion due to the contrast agent, mean values of dispersion before injection (SD PRE ) were subtracted from the mean Tubal leiomyosarcoma 2 value evaluated after injection (SD POST ). The "after-before injection" differences during the whole sequence were noted as DSD. Then the microvascular heterogeneity was normalized and evaluated for different durations. More precisely, to optimize reproducibility between examinations, the parameters were normalized: parameter values were divided by the mean signal of the AIF, providing relative DSD /AIF . To evaluate the best time range for the evaluation of the dispersion, the mean parameters after injection were also evaluated over the first 90 seconds (DSD EARLY/AIF ) and over the last 90 seconds (DSD LATE/AIF ). All parameters normalized by AIF were expressed in % values. Finally, a quantitative analysis was performed with a fourparameter compartmental model previously published, 4 including tissue blood flow (F T ), blood volume fraction (V b ), lag time (D AT ), interstitial volume fraction (V e ), permeability-surface area product (PS), and relative area under the curve, which was normalized by the AIF ( r AUC).
Statistical Analysis
The parameters were compared to the histological analysis (benign, borderline, invasive, with or without carcinomatosis) by performing nonparametric Mann-Whitney tests.
Receiver operating characteristic (ROC) curves and the area under the ROC (AUROC) curve were calculated as a descriptive tool to assess the overall discrimination of parameters and were compared using the De Long et al methodology. 20 A P value of less than 0.05 was considered to indicate a statistically significant difference. Analyses were carried out using MedCalc software (www.medcalc.be. Belgium).
Results
All the results are presented in Tables 2 and 3 .
Comparison of DCE-MRI Parameters Between Benign and Malignant Adnexal Tumors
MORPHOLOGICAL ANALYSIS. The size of the solid component was significantly larger (higher number of pixels) in malignant tumors (849 6 947) than in benign tumors ( 6 443 694) (P 5 0.01).
QUANTITATIVE ANALYSIS. Malignant tumors displayed higher blood tissue flow (F T ), blood volume (V b ), and r AUC than benign tumors (P 5 0.01, P < 0.0001, and P < 0.0001, respectively) and lower delay tissue-artery D AT and interstitial volume (V e ) than benign tumors (P 5 0.0005 and P 5 0.04). No significant difference was found between benign and malignant tumors in the value of the product PS (P 5 0.10).
HETEROGENEITY ANALYSIS. Malignant tumors displayed a higher signal heterogeneity after injection (SD POST ), as a higher increase in heterogeneity due to contrast agent (DSD), than in benign tumors (P < 0.01). The normalized increase in heterogeneity (DSD /AIF ) was also higher in malignant than in benign tumors, whatever the period considered during the first 90 seconds after injection (DSD EARLY/AIF ) or during the last 90 seconds after injection (DSD LATE/AIF ) (P < 0.01). No difference was found regarding heterogeneity parameters before injection (SD PRE ) (P 5 0.29).
The results of ROC curve analysis of all parameters are summarized in Table 3 . The two most relevant factors for discriminating malignant from benign tumors, expressed as the area under the ROC curve, were V b and DSD EARLY/AIF .
Comparison of DCE-MRI Parameters Between Benign and Borderline Adnexal Tumors
No significant difference was found between benign and borderline ovarian tumors for any of the morphological, quantitative, or heterogeneity perfusion parameters tested ( Table 2) .
Comparison of DCE-MRI Parameters Between Borderline and Invasive Adnexal Tumors
MORPHOLOGICAL ANALYSIS. The volume of invasive tumors (975 6 1003) was significantly larger than that of borderline ovarian tumors (278 6 143) (P 5 0.02). Journal of Magnetic Resonance Imaging QUANTITATIVE ANALYSIS. Invasive tumors displayed higher V b and higher r AUC than borderline tumors (P 5 0.0009 and P 5 0.01, respectively). No significant difference in F T , V e , and product PS was found (P 5 0.63, P 5 0.11, P 5 0.46, respectively).
HETEROGENEITY ANALYSIS. We found equivalent results concerning heterogeneity parameters between borderline and invasive tumors and between benign and malignant tumors, with higher heterogeneity parameters for invasive tumors than for borderline tumors ( Table 2 ). The two most relevant factors for discriminating borderline from invasive tumors were V b and DSD EARLY/AIF .
Comparison of DCE-MRI Parameters Between Malignant Tumors With and Without Peritoneal Carcinomatosis
MORPHOLOGICAL ANALYSIS. No difference was found between the volume of malignant tumors with peritoneal carcinomatosis (998 6 1012) and that of malignant tumors without carcinomatosis (714 6 879) (P 5 0.24).
QUANTITATIVE ANALYSIS. Malignant tumors with peritoneal carcinomatosis displayed higher V b and higher r AUC than malignant tumors without peritoneal carcinomatosis. No significant difference in F T , V e , and product PS was found (P 5 0.51, P 5 0.9, and P 5 0.31, respectively). The results of the ROC curve analysis of all parameters are summarized in Table 3 . The two most relevant factors for discriminating between malignant tumors with and without carcinomatosis were DSD /AIF and DSD EARLY/AIF . A solid component that displayed a DSD EARLY/AIF 6% predicted malignancy with a sensitivity of 75.4% and a specificity of 80.8%. Using this cutoff value, 83/113 tumors were correctly classified (accuracy 5 73.4%). Among the malignant tumors, a solid component that displayed a DSD EARLY/AIF 7% predicted invasive malignant tumors with a sensitivity of 76% and a specificity of 72.7%. Using this cutoff value, 46/61 tumors were correctly classified (accuracy 5 75.4%). A solid component that displayed a DSD EARLY/AIF 8% predicted the presence of associated carcinomatosis with a sensitivity of 75% and a specificity of 57.6% (Fig. 3) . Using this cutoff value, 41/61 tumors (67.2%) were correctly classified (accuracy 5 67.2%) (Fig. 4) .
Discussion
Our study demonstrated that the analysis of heterogeneity on DCE-MRI series in adnexal tumors is a very effective method to distinguish benign from malignant tumors, borderline from invasive tumors, and malignant tumors with from malignant tumors without carcinomatosis. The early and normalized increase of heterogeneity measured by DSD EARLY/AIF is the most discriminant parameter of heterogeneity, allowing malignancy to be predicted with a sensitivity of 75.4% and a specificity of 80.8%. This parameter is minimally dependent on acquisition conditions (ie, normalized to AIF) and independent of any mathematical modelization. Moreover, it is obtained in the first 90 seconds after injection, rendering this tool fairly promising for clinical application, given that the technique uses routine imaging sequences. Further developments to allow for online postprocessing are needed to render this technique useful in clinical practice. Preoperative characterization is a crucial issue to plan the optimal surgery in terms of fertility for benign and borderline lesions and prognosis for ovarian cancer. 21 DCE-MRI is widely acknowledged to be useful in characterizing ovarian tumors. [22] [23] [24] [25] [26] Malignant invasive tumors displayed a pathological neoangiogenesis with more permeable microvessels, characterized by a lower pericyte coverage index and a higher expression of VEGFR-2 on both epithelial and endothelial cells than those of benign or borderline tumors. These immunohistochemical parameters are correlated with semiquantitative DCE parameters, including the enhancement maximal amplitude and maximal slope of the timeintensity curve. 2 These features are easy to use in clinical routine but strongly depend on acquisition conditions. Theoretically, quantitative analysis is a more reproducible technique and our study confirms the value of V b and r AUC to distinguish benign, borderline, and invasive tumors with and without carcinomatosis, as previously published. 4 However, our results suggest only a moderate discriminant efficiency for F T , only enabling benign lesions to be differentiated from malignant lesions, in comparison with previous findings. 4 In the current study, V b was the best DCE-MRI quantitative parameter obtained using compartmental modelization, and this result underlines the difficult reproducibility of DCE quantitative parameters. Our study demonstrates that DSD EARLY/AIF has the same overall performance as V b . This type of analysis is independent of the acquisition conditions, including the parameters of the DCE T 1 W sequence and the injection protocol (thanks to the normalization with AIF), and of the choice of model. The analysis of heterogeneity is a way of making a spatial analysis of gadolinium enhancement. 10, 27, 28 The neovasculature of malignant tumors is known to be heterogeneous 9, 29, 30 ; hence, we evaluated the diagnostic value of the analysis of heterogeneity using DCE-MRI to characterize ovarian tumors. Our results demonstrate that the measurement of DSD EARLY/AIF is an accurate way of distinguishing benign from malignant ovarian tumors, as well as DSD /AIF . Whatever the acquisition time considered (ie, early late or overall), the evolution of the variation of SD helped to characterize ovarian tissue, suggesting that this method is robust and the majority of the information required is contained in the first 90 seconds after gadolinium injection. This result concurs with the subjective impression of heterogeneity that was described by Hricak et al after gadolinium injection in ovarian cancer. 8 In a nonselected population of adnexal masses, the heterogeneity may be explained by the presence of mixed solid and cystic component in malignant tumors, in contrast to benign tumors, which are more frequently purely cystic or with a small amount of solid component. However, in our study the evaluation of heterogeneity was based on the enhanced portion (ie, solid component). We even excluded large portions of necrosis, in contrast to previous studies. 5 The heterogeneity could be partly attributed to the presence of small necrotic regions well known to occur in malignant masses due to ischemic effects. In our study, there was no detectable difference in heterogeneity between the different groups before gadolinium injection in a study based on the T 1 -weighted MRI sequence. Recently, the analysis of heterogeneity before injection was evaluated using quantitative T 2 mapping, diffusion weighted, and DCE-MRI in a smaller population of 37 adnexal masses, including cystic lesion without solid component. 5 In that study, only 18 tumors displayed solid tissue. Carter at al suggested that the tumoral heterogeneity assessed by a combination of multiple parameters (including mean, SD, skewness, and kurtosis) was useful to distinguish benign from malignant tumors. 5 However, in their article there was no clear indication on how to apply this result in clinical routine, and borderline ovarian tumors and invasive malignant tumors with carcinomatosis were not analyzed separately. Our study opted for a simple and intuitive histogram-based approach with a very simple analysis of the SD of the distribution of pixels. Using the cutoff of DSD EARLY/AIF 6%, DCE-MRI predicted malignancy with a sensitivity of 75.4% and a specificity of 80.8%. Moreover, this parameter was also accurate in discriminating borderline from invasive tumors and recognized malignant tumors associated with carcinomatosis. This is a major issue in clinical practice because MRI may be less accurate in some locations (eg, mesenteric implants) even using a diffusion-weighted sequence. 31 At present, abdominopelvic computed tomography (CT) remains the gold standard to evaluate peritoneal carcinomatosis but remains limited due a significant rate of false negatives. 32 The standard treatment for a patient with newly diagnosed ovarian cancer has long been the complete removal of the disease by invasive surgery. 33, 34 Recently, Vergote et al demonstrated the value of neoadjuvant chemotherapy to treat locally advanced ovarian cancer, a finding that has critically changed the questions put to the radiologist. 35 As demonstrated in many other organs, the analysis of heterogeneity may help, not only for tumor characterization but also to predict survival, treatment response, and metastatic potential. In a population of ovarian cancer patients, O'Connor et al evaluated a heterogeneity parameter named tumor-enhancing fraction in CT as a predictor of response to chemotherapy, with promising results. 36 It seems that in future it will be necessary to evaluate the correlation of quantitative heterogeneity parameters with survival and recurrence in patients treated for ovarian cancer. In addition to being retrospective, our study has several other limitations. First, we opted for the simplest analysis of heterogeneity, with the distribution of histograms, which are imperfect representations of distributions, where the spatial organization of the parameter map is neglected. 27 Texture analysis including kurtosis and skewness may possibly improve the diagnostic performance, but this was a preliminary study and our objective was to evaluate a technique as simple as possible that would be easy to implement on any routine workstation. Second, as the modeling was done on raw pixels, physiological information may be polluted by noise, and possibly by small solid tissue (ie, solid papillary projections), especially in the borderline subgroup, which would affect the quality of the results. However, a clear increase of DSD EARLY/AIF was observed from benign to invasive malignant tumors with carcinomatosis. Another limitation is that tumor volume was Thomassin-Naggara et al.: Adnexal Tumor Vascular Heterogeneity studied in a single slice (ie, not corresponding to the total tumor volume) and the segmentation was concerned only with enhanced tissue and neglected the unenhanced parts of the tumor, whether cystic or necrotic. However, a similar approach has been adopted by other authors and was justified by the artificial changes that nonenhanced tissue may generate on heterogeneity parameters. 6 Finally, we need to validate our parameters in an external population and include this analysis in addition to classical morphological criteria to evaluate the added value of this analysis in reducing the false-positive and false-negative rates, especially in a population with a lower prevalence of malignant tumors, which could potentially have biased our sensitivity and specificity values.
In conclusion, our study demonstrates the value of heterogeneity analysis on DCE-MRI series to distinguish benign and borderline from malignant ovarian tumors and to predict the presence of peritoneal carcinomatosis. Heterogeneity analysis in DCE-MRI series is a very promising tool and further studies are needed to validate this preliminary result.
